TMPRSS2 and prostate carcinoma: Because of the controversial prognostic utility of TMPRSS2:ERG fusion in prostate cancer, we employed the strategy of a three-marker FISH panel to detect well documented prostate cancer DNA aberrations, including TMPRSS2/ERG rearrangements, AR copy number gain, and PTEN deletion.